SRI International Names Edward G. "Ted" Spack as Senior Director of PharmaSTART Program

MENLO PARK, California - December 1, 2003 - SRI International, a leading independent research institute based in Silicon Valley, announced today that Edward G. “Ted” Spack, Ph.D., has joined SRI as a senior director in its Biosciences Division. In this role, Dr. Spack will coordinate PharmaSTART, an unprecedented collaboration of world-leading research organizations that have joined forces to translate unrealized drug research investments into potentially life-saving drugs.

The PharmaSTART consortium's founding members are Stanford University; the University of California, San Diego; the University of California, San Francisco; and the UCSF campus of the California Institute for Quantitative Biomedical Research (QB3). The University of California, Berkeley also recently joined the consortium.

Through PharmaSTART, SRI offers drug development and consultation services, including guidance on government funding opportunities, to the consortium members' primary investigators. For each qualified project, SRI provides up to 30 hours of complimentary consulting services to create a comprehensive development plan. Each plan identifies the steps required to bring the drug into the clinic efficiently and according to Food and Drug Administration guidelines.

In addition to his PharmaSTART role, Dr. Spack will focus on growing SRI's business in developing biological medicines, especially vaccines and antibody therapies to control biothreat agents and infectious diseases such as HIV and SARS.

Over the course of his career, Dr. Spack has worked on a wide range of therapeutic targets, including autoimmunity, infectious disease, and cancer, using a wide range of drug approaches, including recombinant biologics, humanized monoclonal antibodies, small molecules, and gene therapy.

Most recently, Dr. Spack was senior director of applied research for InterMune, Inc. [Nasdaq: ITMN] a California biopharmaceutical company focused on development of drug therapies for pulmonary and infectious diseases and cancer. Dr. Spack's accomplishments at InterMune include identification and humanization of a monoclonal antibody that blocks toxin delivery.

Prior to InterMune, Dr. Spack was director of product discovery and director of immunology for Valentis, Inc. [Nasdaq: VLTS], which designs DNA-based therapeutics, with a current emphasis on cardiovascular applications. He also worked at Anergen, Inc. (since acquired by Corixa Corporation), where he was program director for multiple sclerosis (MS) and myasthenia gravis drug development efforts.

Dr. Spack has participated in the design and implementation of 10 clinical trials, served on the board of directors of the Myasthenia Gravis Foundation of America, is an advisory member of several medical societies, has authored more than 30 publications, and has been an invited speaker for dozens of presentations. He received a postdoctoral fellowship in immunology from Stanford University, a Ph.D. in cell biology from Johns Hopkins University, and a B.S. from Muhlenberg College.

About SRI International
Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 55 years. The nonprofit research institute performs contract research and development for government agencies, commercial businesses and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.

SRI's Biosciences Division works with government agencies and pharmaceutical companies to provide a broad range of preclinical discovery and development services, including medicinal chemistry, custom synthesis, efficacy and safety evaluations, pharmacokinetics and metabolism studies, analytical chemistry and formulation design and production in GLP and cGMP environments.

# # #

SRI International is a registered trademark of SRI International. All other trademarks are the property of their respective owners.